Today the Dutch drug developer said it would sell a part of the royalty rights for the world’s most expensive treatment Hemgenix to HealthCare Royalty and Sagard Healthcare for up to $400 million in cash.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-05-15 08:01:192023-05-15 10:04:38UniQure to sell royalty interest in blood disorder therapy for up to $400 mln
